Trials / Recruiting
RecruitingNCT05795335
CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
Survival Outcomes, Adverse Events and Predictive Biomarkers for CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer, an Ambispective Single-center Cohort Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 172 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an ambispective, single-center study to evaluate the survival outcomes, adverse events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CDK4/6 inhibitor | CDK4/6 inhibitors |
Timeline
- Start date
- 2023-04-30
- Primary completion
- 2026-04-30
- Completion
- 2028-12-30
- First posted
- 2023-04-03
- Last updated
- 2023-05-16
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05795335. Inclusion in this directory is not an endorsement.